Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
| 対象疾患 | Non Alcoholic Steatohepatitis, Fibrosis |
|---|---|
| 相 | 第1/2相 |
| スポンサー | Stanford University |
| ステータス | 完了 |
| 参加者数 | 53 名 |
| 介入（薬剤） | Idebenone |
| 開始日 | 2021年7月30日 |
| 完了日 | 2023年7月5日 |
| 結果公開日 | 2026年3月27日 |
概要
This is a randomized, placebo-controlled phase 1/2a study to investigate the safety and tolerability of Idebenone in patients 18 years of age or older with non-alcoholic steatohepatitis, with stage 1-3 fibrosis. As secondary end point target engagement and fibrosis improvement will be assessed.
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
| Idebenone | 9 Participants |
|---|---|
| Placebo | 4 Participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
- Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
- Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
- Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
- Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
- Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.